FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer
- PMID: 28751443
- DOI: 10.1158/1078-0432.CCR-17-1337
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer
Abstract
On December 19, 2016, the FDA granted accelerated approval to rucaparib (RUBRACA; Clovis Oncology, Inc.) for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies. The FDA also approved the FoundationFocus CDx BRCA test (Foundation Medicine, Inc.), the first next-generation sequencing-based companion diagnostic, for identifying patients with advanced ovarian cancer eligible for treatment with rucaparib based on detection of deleterious BRCA1 and/or BRCA2 mutations in tumor tissue. Rucaparib's approval was based primarily on efficacy data from 106 patients with BRCA mutation-associated ovarian cancer who had prior treatment with two or more chemotherapies and safety data from 377 patients with ovarian cancer treated with rucaparib 600 mg orally twice daily on two open-label, single-arm trials. Investigator-assessed objective response rate was 54% [57/106; 95% confidence interval (CI), 44-64], and median duration of response was 9.2 months (95% CI, 6.6-11.7). The approved companion diagnostic verified tumor BRCA mutation status retrospectively in 96% (64/67) of patients. Common adverse reactions (≥20%) to rucaparib were nausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea, thrombocytopenia, and dyspnea. This article summarizes the FDA review and data supporting rucaparib's accelerated approval. Clin Cancer Res; 23(23); 7165-70. ©2017 AACRSee related commentary by Kohn et al., p. 7155.
©2017 American Association for Cancer Research.
Comment in
-
The HRD Decision-Which PARP Inhibitor to Use for Whom and When.Clin Cancer Res. 2017 Dec 1;23(23):7155-7157. doi: 10.1158/1078-0432.CCR-17-2186. Epub 2017 Oct 3. Clin Cancer Res. 2017. PMID: 28974545 Free PMC article.
Similar articles
-
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.Clin Cancer Res. 2015 Oct 1;21(19):4257-61. doi: 10.1158/1078-0432.CCR-15-0887. Epub 2015 Jul 17. Clin Cancer Res. 2015. PMID: 26187614 Review.
-
Rucaparib Approved for Ovarian Cancer.Cancer Discov. 2017 Feb;7(2):120-121. doi: 10.1158/2159-8290.CD-NB2016-164. Epub 2017 Jan 5. Cancer Discov. 2017. PMID: 28057616
-
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404. doi: 10.1136/ijgc-2019-000623. Int J Gynecol Cancer. 2019. PMID: 31685558 Clinical Trial.
-
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4. Gynecol Oncol. 2017. PMID: 28882436 Clinical Trial.
-
Rucaparib: First Global Approval.Drugs. 2017 Apr;77(5):585-592. doi: 10.1007/s40265-017-0716-2. Drugs. 2017. PMID: 28247266 Review.
Cited by
-
Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.NPJ Breast Cancer. 2021 Mar 22;7(1):29. doi: 10.1038/s41523-021-00240-w. NPJ Breast Cancer. 2021. PMID: 33753748 Free PMC article.
-
Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.Drug Des Devel Ther. 2018 Sep 17;12:3013-3019. doi: 10.2147/DDDT.S164553. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30271116 Free PMC article.
-
Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.J Pers Med. 2021 Jun 5;11(6):518. doi: 10.3390/jpm11060518. J Pers Med. 2021. PMID: 34198738 Free PMC article. Review.
-
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.Cancers (Basel). 2020 Jul 25;12(8):2054. doi: 10.3390/cancers12082054. Cancers (Basel). 2020. PMID: 32722408 Free PMC article. Review.
-
A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).Int J Oncol. 2021 Jul;59(1):53. doi: 10.3892/ijo.2021.5233. Epub 2021 Jun 16. Int J Oncol. 2021. PMID: 34132354 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous